<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319369</url>
  </required_header>
  <id_info>
    <org_study_id>DS3032-A-U102</org_study_id>
    <nct_id>NCT02319369</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of DS-3032b, an Oral Murine Double Minute (mdm2) Oncogene Inhibitor, in Subjects With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability
      and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in
      subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic
      Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or high risk MDS in Part
      1-Dose Escalation and refractory or relapsed AML or high risk Myelodysplastic Syndrome (MDS)
      in Part 2-Dose Expansion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number and severity of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the safety and tolerability of DS 3032b in subjects with refractory or relapsed AML or ALL, CML in blast phase, or high risk MDS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>2 months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) or tentative recommended Phase 2 dose (RP2D) of DS-3032b estimated by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM), and on an overall assessment of safety data from subsequent cycles and drug exposure/Pharmacodynamic (PDy) response information collected at all different doses tested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic profile of DS-3032b (Cmax, Tmax, and daily exposure)</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the Cmax, Tmax, and daily exposure of DS-3032a (the free form of DS-3032b) following single and multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in macrophage inhibitory cytokine-1 (MIC-1) levels</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the pharmacodynamic (PDy) effect of DS-3032b on macrophage inhibitory cytokine-1 (MIC-1) levels in serum.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>DS-3032b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-3032b will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg DS-3032b</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-3032b</intervention_name>
    <description>DS-3032b will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg DS-3032b</description>
    <arm_group_label>DS-3032b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has one of the following diagnoses: Subjects must have refractory or relapsed AML or
             ALL, CML in blast phase, or high risk MDS (defined by Revised International Prognostic
             Scoring System [IPSS-R] score as High or Very High for inclusion in Part 1 of the
             study. Subjects must have refractory or relapsed AML or high-risk MDS (defined by
             IPSS-R score as High or Very High for inclusion in Part 2 of the study.

          -  Man or woman &gt;= 18 years old.

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

          -  Has adequate renal function, defined as: Creatinine clearance &gt;=60 mL/min, as
             calculated using the modified Cockcroft Gault equation, ([{140 - age in years} ×
             {actual weight in kg}] divided by [{72 × serum creatinine in mg/dL} multiply by 0.85
             if female]), OR creatinine =&lt; 1.5 X ULN

          -  Has adequate hepatic function, defined as:

          -  AST/ALT =&lt;3 X ULN; -Bilirubin =&lt;1.5 X ULN, unless resulting from hemolysis

          -  Has adequate blood clotting function, defined as: - International normalized ratio and
             activated partial thromboplastin time =&lt;1.5 XULN

          -  Subject is able to provide written informed consent, comply with protocol visits and
             procedures, and take oral medication, and does not have any active infection or
             comorbidity that would interfere with therapy.

          -  Subject (male and female) of childbearing/ reproductive potential must agree to use
             double barrier contraceptive measures or avoid intercourse during the study and for 90
             days after the last dose of study drug.

          -  Subject must be fully informed about their illness and the investigational nature of
             the study protocol (including foreseeable risks and possible side effects).

          -  Subject must sign and date an Institutional Review Board-approved informed consent
             form (including Health Insurance Portability and Accountability Act authorization, if
             applicable) before performance of any study-specific procedures or tests.

          -  Able and willing to provide bone marrow biopsies/aspirates as requested by the
             protocol.

          -  Is willing to undergo malignancy genotyping for TP53 gene mutation, insertion, or
             deletion at screening.

          -  Has a life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Has a diagnosis of acute promyelocytic leukemia.

          -  Has a malignancy that contains a non synonymous mutation, insertion, or deletion in
             the TP53 gene determined previously or at screening.

          -  Presence of central nervous system involvement of leukemia or a history of primary
             central nervous system leukemia.

          -  Has a second concurrent primary malignancy that required active treatment within the
             previous 2 years, except for localized cancers that have apparently been cured, such
             as non-melanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the
             cervix or breast.

          -  Any condition that would preclude adequate absorption of DS-3032b, including
             refractory nausea and vomiting, malabsorption, biliary shunt, significant bowel
             resection, and/or graft-versus-host disease (GVHD) affecting the gut.

          -  Has an uncontrolled infection requiring intravenous antibiotics, antivirals, or
             antifungals, known human immunodeficiency virus infection, or active hepatitis B or C
             infection.

          -  Has a concomitant medical condition that would in the opinion of the Investigator
             increase the risk of toxicity.

          -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities
             (other than alopecia) not yet resolved to NCI-CTCAE v4, Grade =&lt;1 or baseline.
             Subjects with chronic Grade 2 toxicities may be eligible per discretion of the
             Investigator and Sponsor (eg, Grade 2 chemotherapy-induced neuropathy).

          -  Has received Hematopoietic Stem Cell Transplantation (HSCT) within 60 days of the
             first dose of DS-3032b, is on immunosuppressive therapy post-HSCT at the time of
             screening, or has clinically significant GVHD (use of topical steroids for ongoing
             skin GVHD will be permitted). Subjects must have a washout period of &gt;=2 weeks or at
             least 4 half-lives from their last systemic immunosuppressive treatment for GVHD.

          -  Is receiving concomitant treatment with a strong inhibitor or inducer of CYP3A4/5.

          -  Received any therapies intended to treat malignancy within 14 days of first receipt of
             DS-3032b (except for hydroxyurea, which must be discontinued at least 48 hours prior
             to study treatment).

          -  Had major surgery within 4 weeks prior to study drug treatment.

          -  Participated in a therapeutic clinical study within 3 weeks before study drug
             treatment, or current participation in other therapeutic investigational procedures.

          -  Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the
             mean QTcF interval is &gt;450 ms for males or &gt;470 ms for females based on triplicate
             electrocardiograms (ECGs).

          -  Pregnant or breastfeeding.

          -  Substance abuse or medical, psychological, or social conditions that, in the opinion
             of the Investigator, may interfere with the subject's participation in the clinical
             study or evaluation of the clinical study results.

          -  Prior treatment with an MDM2 inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Ruwe, PhD</last_name>
    <phone>513-579-9911</phone>
    <phone_ext>2353</phone_ext>
    <email>a.ruwe@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>M D Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

